Sewanti Limaye - Concepedia

Author

Sewanti Limaye

Dana-Farber Cancer Institute ORCID

Also Known As

Gyula Ostoros, S. A. Limaye, S. Limaye, S.A. Limaye, Sewanti A. Limaye, Sewanti Atul Limaye, Sewanti Limaye

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Brigham and Women's Hospital Icahn School of Medicine at Mount Sinai Harvard University Massachusetts General Hospital

About

Sewanti Limaye is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	1.1K
2	Health Sciences	5	5	873
3	Nursing	1	1	39
4	Allergy	1	1	13
5	Cell Biology	1	1	10

Sewanti Limaye

Publications

Citations

H-Index

Page 1

	Year	Citations
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial Robert I. Haddad, Anne O’Neill, Guilherme Rabinowits, The Lancet Oncology Advanced HeadConcurrent ChemoradiotherapyRadiation TherapyMedicineRandomised Phase 3	2013	735
Trastuzumab for the Treatment of Salivary Duct Carcinoma Sewanti Limaye, Marshall R. Posner, Jeffrey F. Krane, The Oncologist	2013	181
Identifying Vulnerable Older Adults with Cancer: Integrating Geriatric Assessment into Oncology Practice Arti Hurria, Stuart M. Lichtman, Jonathan Gardes, Journal of the American Geriatrics Society	2007	144
Distress in Older Patients With Cancer Arti Hurria, Daneng Li, Kurt Hansen, Journal of Clinical Oncology	2009	130
Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy Sewanti Limaye, Robert I. Haddad, Fiona Cilli, Cancer	2013	122
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study Glenn J. Hanna, Naifa L. Busaidy, Nicole G. Chau, Clinical Cancer Research	2018	120
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck Joshua Bauml, Ravi Vinnakota, Yeun‐Hee Anna Park, JNCI Journal of the National Cancer Institute	2018	113
A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia Matthew Kaufman, Sewanti Limaye, Nancy Driscoll, Leukemia & lymphoma/Leukemia and lymphoma Chronic Lymphocytic LeukemiaMedian DurationImmunologyPathologyPharmacotherapy	2009	83
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) Sewanti Limaye, Sarah Riley, Sihai Dave Zhao, Oral Oncology Malignant DiseaseMedicineHead And Neck CancerDermatologyCancer Treatment	2013	59
Treatment of advanced non-small-cell lung cancer Kumar Prabhash, Amish Vora, Sewanti Limaye, Cancer Research Statistics and Treatment Preclinical TherapeuticsSurgical OncologyAdvanced Lung DiseaseCancer ManagementPathology	2021	45

Page 1